12:00 AM
Jun 22, 1998
 |  BioCentury  |  Finance

Centaur plans huge Swiss IPO

Centaur plans huge Swiss IPO

Centaur filed last week for an $89.7 million international IPO. The U.S. company will seek quotation on the Swiss stock exchange, and will not list the shares in the U.S. The company, which lost $1 million on $2.9 million in revenues in the first quarter, was mum on how many shares it planned to sell.

Centaur is developing nitrone-related therapeutics (NRTs) to treat diseases involving oxidative stress. It is conducting several Phase I trials in indications including AIDS dementia, oxidative stress-related inflammation and Parkinson's disease.

A group of investors - including Graham Cooke and Concord Partners II, Menlo Ventures IV, Bismuth Investments, Paul F. Glenn and the Glenn Foundation, Charter Ventures, and Neuroscience Partners - owns 43.9 percent prior to the IPO.

HAIRCUT: Gliatech (GLIA) sold a watered-down $18 million follow-on offering of 1.5 million shares at $12. The stock was at $16.50 when it filed to sell 2 million shares on...

Read the full 762 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >